Dr. G interviews Dr. Andronica Handie, DPM, MS about combining his background in nuclear medicine and biopharmaceutical sciences with podiatric innovation to tackle onychomycosis in diabetic patients. They discuss TripleClear HF, an all‑natural topical antifungal using nanotechnology to penetrate nail plates, trial results showing marked reductions in nail thickness, and safety advantages over systemic antifungals. Takeaways: TripleClear HF can be used preventively or as primary therapy to reduce fungal burden, improve compliance through rapid visible effects, and may play a role in long‑term diabetic foot hygiene and limb preservation alongside blood sugar control and daily foot checks.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related